Yousif Capital Management LLC Has $1.54 Million Stock Position in DaVita Inc. (NYSE:DVA)

Yousif Capital Management LLC reduced its position in shares of DaVita Inc. (NYSE:DVA) by 3.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,044 shares of the company’s stock after selling 318 shares during the period. Yousif Capital Management LLC’s holdings in DaVita were worth $1,536,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its holdings in shares of DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company’s stock worth $405,000 after buying an additional 227 shares during the period. Hussman Strategic Advisors Inc. boosted its holdings in shares of DaVita by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock worth $3,769,000 after buying an additional 16,800 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of DaVita during the 4th quarter worth $597,000. Convergence Investment Partners LLC boosted its holdings in shares of DaVita by 33.2% during the 4th quarter. Convergence Investment Partners LLC now owns 11,389 shares of the company’s stock worth $1,703,000 after buying an additional 2,836 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in shares of DaVita during the 4th quarter worth $5,636,000. 90.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on DVA. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Truist Financial reduced their price target on shares of DaVita from $170.00 to $164.00 and set a “hold” rating for the company in a report on Monday, May 19th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $164.50.

DaVita Price Performance

NYSE:DVA opened at $137.83 on Tuesday. The company has a 50-day moving average of $141.25 and a 200-day moving average of $150.78. The company has a market capitalization of $10.41 billion, a price-to-earnings ratio of 12.83, a PEG ratio of 1.07 and a beta of 1.11. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping analysts’ consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $2.26 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.